NCT00171951View on ClinicalTrials.gov

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 13, 2004

Primary Completion Date

July 8, 2013

Study Completion Date

July 8, 2013

Conditions
Cushing Disease
Interventions
DRUG

Pasireotide

Pasireotide 600 μg or 900 μg was administered as an SC injection.

Trial Locations (8)

45122

Novartis Investigative Site, Essen

60126

Novartis Investigative Site, Ancona

75006

Novartis Investigative Site, Paris

80336

Novartis Investigative Site, München

97239

Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU., Portland

02114

Massachusetts General Hospital, Boston

19104-6149

University of Pennsylvania Medical Center, Philadelphia

BT12 6BA

Novartis Investigative Site, Belfast

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY